Fms-like tyrosine kinase 3 (FLT3) is expressed in hematopoietic progenitor cells. An internal tandem duplication (ITD) of FLT3 (FLT3/ITD) is the most frequent mutation in human adult acute myeloid leukemia (AML). FLT3/ITD contributes to the constitutive activation of FLT3 itself and its downstream signal components, mitogen-activated protein kinase and signal transducers and activators of transcription 5 (STAT5), and enables interleukin (IL)-3-dependent cell lines to grow autonomously. In the present study, we showed the specific association of FLT3/ITD with Lyn, which led to the phosphorylation of Lyn in vivo. We also demonstrated that FLT3/ITD receptors displayed a higher affinity to bind to Lyn than wild-type FLT3 receptors in vitro and that this affinity was relative to the intensity of tyrosil phosphorylation of the receptor. Both treatment with small interfering RNA (siRNA) targeting Lyn and the Src family kinase inhibitor PP2 suppressed the IL-3-independent growth of FLT3/ITD-expressing 32D cells (FLT3/ ITD-32D), reducing the constitutive phosphorylation of Lyn and STAT5. PP2 treatment of mice transplanted with FLT3/ITD-32D cells blocked the onset of tumors and decreased the size of established tumors. These results demonstrate that Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
Introduction
Fms-like tyrosine kinase 3 (FLT3) is a member of the class III receptor tyrosine kinase (RTK) family and is preferentially expressed on hematopoietic stem cells. 1 Signal transduction by FLT3 plays a critical role in hematopoiesis, mediating stem/ progenitor cell differentiation and proliferation. [1] [2] [3] Internal tandem duplication (ITD) within the juxtamembrane domain of FLT3 (FLT3/ITD) occurs in approximately 20% of adult patients suffering from acute myeloid leukemia (AML). 4, 5 These mutations cause constitutive activation of the receptor and its downstream signal components, which confers a growth advantage on cells. [6] [7] [8] [9] Involvement of FLT3/ITD in leukemia development as a first or second hit has been revealed in animal models. [10] [11] [12] The expression of FLT3/ITD has been reported to be associated with disease progression in myelodysplasia and a poor prognosis in AML. 5, [13] [14] [15] [16] These findings suggest that disordered FLT3 signals have a critical role in the development and progression of leukemia. Numerous studies concerning the signal transduction of FLT3/ ITD have revealed its aberrant constitutive activation of downstream signal components such as mitogen-activated protein (MAP) kinase, signal transducers and activators of transcription 5 (STAT5), and Akt. [6] [7] [8] In particular, STAT5 is phosphorylated exclusively in FLT3/ITD transfectants, not in wild-type FLT3 transfectants even upon ligand stimulation, and is thought to be a critical component of aberrant growth and/or antiapoptotic signaling induced by FLT3/ITD. However, the signaling component(s) linking FLT3/ITD to STAT5 have yet to be identified.
The non-receptor tyrosine kinase Lyn is a member of the Src family kinases (SFK) and is expressed predominantly in hematopoietic tissues. 17 SFK are thought to interact with a cell surface receptor and participate in initial signal transduction via this receptor. 18 It is reported that several RTK, including c-Fms, PDGF receptor b, c-Kit, and epidermal growth factor receptor (EGFR), activate SFK. 18, 19 Also, SFK have been reported to activate STAT pathways and play a role in cytokine-induced cell proliferation. 20 Originally Lyn was cloned as a signal component of B-cell antigen receptor, but recent studies revealed that Lyn also acted as a signal component of cytokine receptors such as erythropoietin receptor, CSF-1 receptor, and c-Kit, and promoted mitogenic signaling from them. 19, 21, 22 In the present study, we showed the specific association of FLT3/ITD with Lyn, which led to the phosphorylation of Lyn in vivo. We also demonstrated that FLT3/ITD receptors displayed a higher affinity to bind to Lyn than wild-type FLT3 receptors in vitro, and that this affinity was relative to the intensity of tyrosil phosphorylation of the receptor. The significance of the phosphorylation of Lyn in FLT3/ ITD-induced growth signaling was then confirmed by silencing with small interfering RNA (siRNA) and by inhibition with a selective Src family kinase (SFK) inhibitor. More importantly, we demonstrated that SFK inhibitor could prevent tumor development associated with FLT3/ITD and improve prognosis in a mouse model. These findings strongly suggest the potential of Lyn as a therapeutic target in the treatment of AML with FLT3/ITD.
Materials and methods

Cells
IL-3-dependent hematopoietic progenitor cell line 32D was stably transfected with wild-type FLT3 or FLT3/ITD (containing a tandem repeat of amino acids (aa) 583-602), and was designated as Wt FLT3-32D and FLT3/ITD-32D, respectively, as described previously. 6 Antibodies, reagents, and plasmids Polyclonal rabbit antibody against Lyn, FLT3 (C-20), Jak2 (C-20), c-Src, Fyn, Lck, and c-Yes, and monoclonal mouse antibody against Lyn (H-6) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Phospho-specific polyclonal rabbit antibody against JAK2, STAT5, p44/42 MAPK, Akt, Shc, and Src Family (Tyr416) and non-phospho-specific polyclonal rabbit antibody against p44/42 MAPK, Akt, and Shc were obtained from Cell Signaling Technology (Beverly, MA, USA). Antiphosphotyrosine (PY-20), anti-STAT5, and anti-Hck monoclonal mouse antibody were from Transduction Laboratory (Lexington, KY, USA). Anti-glutathione S transferase (GST) polyclonal goat antibody was obtained from Pharmacia (Uppsala, Sweden). PP2 was purchased from Calbiochem (La Jolla, CA, USA) and dissolved in dimethylsulfoxide (DMSO).
Lyn(full)/pGEX, Lyn(1-222)/pGEX, Lyn(1-169)/pGEX, and Lyn(106-222)/pGEX encoding GST-fused full-length human Lyn B and its partial fragments corresponding to aa 1-222, 1-169, and 106-222 were constructed by digestion of LynB/ pHNGAP, 23 and insertion into pGEX5X-1 vector (Pharmacia). For in vitro synthesis of FLT3 proteins, restriction enzymedigested cDNA fragments of human wild-type FLT3 and FLT3/ ITD with a tandem repeat of aa 583-602 were subcloned into pcDNA3.1 vector (Invitrogen, Carlsbad, CA, USA) and designated as Wt FLT3/pcDNA and FLT3/ITD/pcDNA, respectively. 4F Wt FLT3/pcDNA and 8F FLT3/ITD/pcDNA were made by polymerase chain reaction (PCR) mutagenesis using the QuikChanget site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA).
Preparation of cell lysate, immunoprecipitation, immunoblotting, and FLT3-Lyn-binding assays
For preparation of the cell lysate, after cytokine starvation, cells were lysed with lysis buffer (50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% Nonidet P-40, 0.1% sodium dodecyl sulfate (SDS), 1 mM sodium vanadate, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM dithiothreitol (DTT), 10 mM sodium fluoride, and 10 mg/ml of aprotinin, leupeptin, and pepstatin (A). Immunoprecipitation and immunoblotting were performed as previously described. 24 Binding assays in vitro and dephosphorylation of proteins were performed as previously described 24 with minimal modification.
Silencing Lyn by siRNA
Two kinds of pre-designed siRNA targeting exon 5, and exons 7 and 8 (siRNA ID: 156196 and 156197, respectively) of Lyn were purchased from Ambion (Austin, TX, USA). BLOCK-iT Fluorescent Oligot was obtained from Invitrogen and used as control siRNA. Mixtures of two siRNAs (1.5 mg each) targeting Lyn and 3 mg of control siRNA were transiently transfected using Nucleofector system (amaxa biosystems, Gaithersburg, MD, USA), according to the manufacturer's guidelines.
In vivo administration of PP2
Eight-week-old female C3H/HeNCrj mice were purchased from Charles River Japan Inc. (Atsugi, Japan). They were kept under standard laboratory conditions according to the guidelines of the Institute for Laboratory Animal Research, Nagoya University School of Medicine. This study was approved by the Institutional Ethics Committee for Laboratory Animals Used in Experimental Research. One million FLT3/ITD-32D cells or Wt FLT3-32D cells were subcutaneously inoculated into the back of each mouse. Treatment with PP2 was started on the indicated day. Tumor size was monitored twice a week. Tumor weight (TW) was evaluated using the following formula: 
Results
Lyn phosphorylation and its association with FLT3 are observed in FLT3/ITD-transfected 32D cells but not in wild-type FLT3-transfected cells
The present study focused on the pathway of FLT3/ITD signaling to STAT5. We first investigated the phosphorylation status of JAK2, a well-known component upstream of STAT5 in the JAK-STAT pathway, but found no activation by either wild-type FLT3 or FLT3/ITD (Supplementary Figure 1a) . Src family kinases (SFK) are reported as an alternative pathway to activate STAT, especially under receptor tyrosine kinase signaling. 18, 20 To test whether any SFK are downstream components of FLT3 signaling, we first compared the phosphorylation status of Src and Lyn in Wt FLT3-32D and FLT3/ITD-32D cells with or without cytokine stimulation. We found no significant difference in Src phosphorylation in Wt FLT3-32D compared to FLT3/ITD-32D, regardless of cytokine stimulation (Supplementary Figure 1b) . On the other hand, Lyn phosphorylation was observed in FLT3/ ITD-32D cells constitutively but not in Wt FLT3-32D cells even after FLT3 ligand stimulation ( Figure 1a) .
We next performed a co-immunoprecipitation assay using anti-FLT3 antibody for immunoprecipitation and anti-Lyn antibody for immunoblotting to test whether FLT3 association with Lyn was also FLT3/ITD-specific. The association also bound to Lyn, although the binding was much weaker than that of FLT3/ITD, suggesting that the mutant specificity of FLT3 association with Lyn was not absolute. We investigated the tyrosil-phosphorylation status of the FLT3 used in the in vitro binding assay to clarify whether it affected the affinity of FLT3 for Lyn as in other RTK. 25 FLT3 synthesized in a reticulocyte lysate system underwent auto-tyrosine phosphorylation, and the phosphorylation of FLT3/ITD was much stronger than that of wild-type FLT3 (Figure 2a, right panel) . These data suggest that the interaction between FLT3 and Lyn may be dependent on the tyrosine phosphorylation of FLT3, and that the difference of the tyrosyl-phosphorylation status of FLT3 might account for the observed differences of its binding affinity for Lyn. To confirm the dependency of binding on phosphorylation, we performed in vitro binding assays using dephosphorylated FLT3. Expectedly, dephosphorylation of FLT3 completely abolished the association of both wild-type and mutant FLT3 with Lyn, which suggested their dependency on FLT3 phosphorylation (Figure 2b ). To further clarify the FLT3-tyrosyl phosphorylation Lyn
(SH2) domain of Lyn was involved in the association, because the SH2 domain was responsible for the recognition of phosphorylated tyrosine in many cases. In addition, we also studied the effect of tyrosine-to-phenylalanine substitution at the juxtamembrane domain of FLT3, which is the most possible interaction domain with Lyn. In vitro binding assay using GST-fused various parts of Lyn clearly showed the involvement of the SH2 domain of Lyn in its association with FLT3/ITD (Figure 2d ). We substituted four tyrosine residues existing in the juxtamembrane domain of Wt FLT3 and eight of FLT3/ITD to phenylalanine (4F substitution and 8F substitution, respectively) and designated them as 4F Wt FLT3 and 8F FLT3/ ITD, respectively (Figure 2c ). In the in vitro binding assay, Lyn associated with 4F Wt FLT3 and 8F FLT3/ITD with reduced affinity, approximately 30% of Wt FLT3 and FLT3/ITD, respectively (Figure 2e, left panel) . 4F and 8F substitution also significantly reduced the tyrosyl phosphorylation of Wt FLT3 and FLT3/ITD, respectively (Figure 2e, right panel) . These results indicate that these substituted tyrosine residues will be phosphorylation sites of Wt FLT3 and FLT3/ITD in their autophosphorylation and responsible for their association with Lyn, and that these tyrosyl phosphorylation may be recognized by the SH2 domain of Lyn.
Specific inhibition of Lyn signal by siRNA specifically suppresses FLT3/ITD-induced cell growth
We further studied the significance of Lyn activation in FLT3/ ITD-induced autonomous cell growth, trying to downregulate Lyn expression by using siRNA against Lyn. Successful silencing of Lyn expression in FLT3/ITD-32D, approximately 90% reduction, was confirmed by immunoblotting, and the specificity of silencing was also confirmed by immunoblotting; that is, the expressions of five other members of SFK were not significantly affected (Figure 3a) . The effect of Lyn silencing on FLT3/ITD signal was investigated by immunoblotting with phospho-specific antibodies against each signal component. The phosphorylation of SFK was significantly reduced, to approximately 20% level of the control. Taken together with that expressions of other SFK members were not affected, the reduction of SFK phosphorylation will come from silencing of Lyn. This indicates that the phosphorylation detected by antiphospho-SFK antibody in FLT3/ITD-32D is mainly Lyn phosphorylation and that this antibody can be used to observe Lyn phosphorylation in FLT3/ITD-32D. STAT5 phosphorylation was reduced to approximately 50% level of the control, whereas the phosphorylation of other signal components, MAP kinase, Akt, and Shc, were not affected (Figure 3b ). STAT5 phosphorylation was obviously reduced by Lyn silencing although it was not completely abolished. These findings suggest that Lyn is strongly responsible for STAT5 phosphorylation, but do not exclude the involvement of other mechanisms.
The effect of siRNA against Lyn on the growth of 32D transfectants was then examined. In the absence of IL-3, the growth of FLT/ITD 32D was significantly suppressed by Lyn siRNA (Figure 3c ), whereas it did not affect the growth of both Wt FLT3-32D and FLT3/ITD-32D in the presence of IL-3. FLt3-ligand-induced growth of Wt FLT3-32D was also not affected (Figure 3c and d) . These results indicate that Lyn will be more important for cell growth induced by FLT3/ITD signal than that by wild-type FLT3 signal or IL-3 signal.
Growth inhibition of FLT3/ITD-32D by PP2, an SFK inhibitor
To confirm the importance of Lyn in the induction of cell growth by FLT3/ITD, the effects of PP2, a SFK-selective inhibitor, 26 on the growth of Wt FLT3-32D and FLT3/ITD-32D were investigated. Both types of cells were cultured with various concentrations of PP2 for 24 h. The growth-inhibitory effect was clearly dose dependent and stronger on FLT3/ITD-32D cultured without IL-3 than on Wt FLT3-32D and FLT3/ITD-32D with IL-3. The GI 50 of PP2 for FLT3/ITD-32D cells incubated without IL-3 was less than one-third of that for Wt FLT3-32D and FLT3/ITD-32D cells with IL-3 (5 mM vs. 17.7 mM) (Figure 4a ). We also compared the growth curve of FLT3/ITD-32D with or without IL-3 in the presence of 10 mM PP2. The growth of FLT3/ITD-32D was inhibited completely by PP2 in the absence of IL-3, although growth inhibition was observed to some extent in the presence of IL-3 ( Figure 4b ). PP2 growth inhibition seems to have a preference for growth induced by FLT3/ITD over that by IL-3, suggesting its potential as an antitumor drug of FLT3/ITDinduced cancer. We next investigated the effect of PP2 on the phosphorylation of signal components induced by FLT3/ITD and IL-3 in timecourse experiments by immunoblotting with phospho-specific antibody against each component or anti-phospho-tyrosine antibody. FLT3 phosphorylation in FLT3/ITD-32D was unchanged after the addition of 10 mM PP2 (Figure 4c, top panel) . 
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However, under the condition without IL-3, we found the rapid disappearance of SFK phosphorylation within 1 h after PP2 treatment, and the disappearance of STAT5 phosphorylation followed within 6 h. Mild reduction of MAP kinase phosphorylation started 12 h after treatment, and Akt and Shc were not affected (Figure 4c ). No phosphorylation of JAK2 was observed at any time point (data not shown). On the other hand, under IL-3 stimulation, we identified the phosphorylation of JAK2, which was weakly inhibited by PP2 12 h after treatment, and residual phosphorylation of STAT5 consistent with that of JAK2. The reduction of MAP kinase phosphorylation was observed at a similar level as that under the condition without IL-3 (Figure 4d ). Akt and Shc phosphorylation were not affected (data not shown). We could not judge whether the observed reduction of the phosphorylation signal was the direct effect of Lyn inhibition, the effect of inhibition of other SFK than Lyn, or the one of a kinase(s) other than SFK; therefore, we could not determine the downstream signal components of Lyn only from these results. Nevertheless, signal inhibition by PP2 seemed to have a preference for STAT5, which was compatible with the hypothesis that Lyn is an upstream component of STAT5.
Therapeutic effect of PP2 on tumors with FLT3/ITD in a murine model
To examine the possibility of using SFK inhibitors as therapeutic reagents for FLT3/ITD-induced cancer, we used a murine model of FLT3/ITD-induced tumor, in which FLT3/ITD-32D cells were inoculated into non-irradiated mice. 27 Six mice were inoculated with FLT3/ITD-32D cells subcutaneously on day 1, and were injected intraperitoneally with either 5 or 10 mg of PP2 dissolved in DMSO or DMSO alone twice a week from days 4 to 63. Subcutaneous tumors grew rapidly from day 25 in control mice, which were dead by day 45. In contrast, no detectable tumors developed by day 63 in the group treated with 10 mg of PP2. The mice treated with 5 mg of PP2 developed subcutaneous tumors The effect of PP2 on tumor development in vivo was then examined. Six mice were inoculated with FLT3/ITD-32D cells and injected with PP2 or DMSO alone (as controls) after tumor development (day 25). In control mice, the subcutaneous tumors underwent very rapid proliferation and all mice died by day 45. On the other hand, tumor development was gradual in mice treated with 30 mg of PP2 and all of these mice were still alive at day 63. Furthermore, stronger growth inhibition was obtained with treatment with 60 mg of PP2: the tumors became too small to detect externally by day 35 (Figure 5b ). Both mice in this group were still alive without tumor growth for more than 20 weeks after PP2 injections. These results suggest that PP2 was a safe and effective agent for the prevention and treatment of FLT3/ITD-induced tumors at the doses used.
Discussion
Our findings that both STAT5 and Lyn were phosphorylated specifically in FLT3/ITD-32D, and that STAT5 phosphorylation was reduced by silencing Lyn with siRNA suggest that Lyn may be an intermediate signal component linking FLT3/ITD to STAT5 in FLT3/ITD-32D. We previously reported that the constitutive activation of Lyn by forced dimerization conferred IL-3-independent growth on 32D cells. 23 Recently, we found that STAT5 was constitutively phosphorylated in those cells (Akihiro Abe, unpublished data). These findings indicate the existence of the Lyn-STAT5 pathway, which is responsible for cell growth induced by FLT3/ITD and the potential of Lyn as a good target for the treatment of AML with FLT3/ITD. Notably, Lyn silencing by siRNA could not completely block the phosphorylation of STAT5 and autonomous cell growth in FLT3/ITD-32D cells (Figure 3b and d) . These can be explained by residual Lyn expression (approximately 10% of control) due to incomplete silencing; however, it raises another possibility that other kinase(s), especially other members of SFK, are also involved in STAT5 phosphorylation and autonomous cell growth in FLT3/ ITD-32D. The activation of SFK other than Lyn and Src by FLT3/ ITD should also be tested.
The direct interaction between FLT3 and Lyn demonstrated in in vitro binding assays indicates that Lyn is the initial component of this FLT3/ITD-specific signaling pathway in 32D cells. SFK are usually anchored to the cell membrane, directly bind to cytokine receptors at the juxtamembrane domain, and take part in initial signaling events. 18 The direct association of Lyn with c-kit at the juxtamembrane domain has already been reported. 19 We also showed the difference of FLT3 affinity to Lyn in vitro between wild-type FLT3 and FLT3/ITD. Our findings of the different phosphorylation statuses of synthesized FLT3 (Figure 2a ) and the requirement of tyrosyl phosphorylation of FLT3 for this interaction (Figure 2b ) can explain this difference of affinity to Lyn. In the same way, the mutant specificity of this association in 32D cells might come from differences in the phosphorylation status of FLT3 in vivo, that is, the liganddependent transient phosphorylation of wild-type FLT3 and the constitutive phosphorylation of FLT3/ITD. Recently, other groups have reported Lyn activation by wild-type FLT3 with ligand stimulation. 28 This discrepancy might come from the different experimental conditions, such as the type of cell line, expression levels of the receptor, and the activity of FLT3 ligand. These differences might affect the phosphorylation status, intensity and duration, of wild-type FLT3, which led to the different phosphorylation status of Lyn. We confirmed the equal expression of wild-type FLT3 and FLT3/ITD 6 and that the phosphorylation of wild-type FLT3 was transient in our 32D transfectant (data not shown).
Of note in our previous report, 32D cells transfected with 8F FLT3/ITD-32D still showed IL-3-independent cell growth and constitutive phosphorylation of STAT5 and MAP kinase comparable to those of FLT3/ITD-32D. 29 These results suggest that FLT3/ITD will have other binding site(s) for Lyn outside the juxtamembrane domain and that such residual interaction with Lyn may be enough to cause autonomous growth and constitutive phosphorylation of STAT5 in 32D cells. For precise elucidation of this initial signaling event, identification and mutagenesis of the residual binding sites of FLT3 which will be its residual phosphorylated tyrosine, and the cell growth analysis of 32D transfected with Lyn-interaction-defective mutant of FLT3/ITD will be required.
Although PP2 was not a specific growth inhibitor, its growthinhibitory effect on FLT3/ITD-induced cell growth was significantly stronger than that on IL-3-induced cell growth (Figure 4a  and b) . Therefore, PP2 is expected to have potential as an antitumor drug for FLT3/ITD-induced cancer, which was further confirmed in an animal model (Figure 5a and b) . Several potent FLT3 kinase inhibitors are under development, especially PKC412, CEP-701, and MLN-518 are now being assessed in phase II clinical trials. However, the effects of these drugs are not currently sufficient to achieve complete remission of the disease as a single agent like other molecular targeting agents such as all-trans retinoic acid for acute promyeloid leukemia and imatinib for chronic myeloid leukemia (CML). [30] [31] [32] The combined administration of these drugs and PP2 targeting FLT3/ITD itself and its downstream component Lyn kinase may be the optimal strategy. Further investigation of the safety and effect of PP2 administration in vivo, including a clinical trial, will be required.
In conclusion, we found that Lyn is a new signaling component of the FLT3/ITD-specific pathway linking FLT3/ITD to STAT5, and demonstrated the potential of SFK inhibitors as drugs for AML with FLT3/ITD. Our findings provided new insights into the mechanism of leukemogenesis induced by FLT3/ITD and useful information for planning strategies for the treatment of AML with FLT3/ITD. Further elucidation of the mechanism of Lyn activation by FLT3/ITD and the development of SFK inhibitors, including PP2, as drugs for AML with FLT3/ITD are required.
